CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project focuses on developing Artificial T cells (ArTCells) that mimic the function of natural T cells to target and kill tumor cells. This innovative approach aims to provide a safer and more effective alternative to existing T cell therapies for cancer treatment.
T cells play a central role in anti-tumor immune protection.
While their ability to target and eliminate emerging tumor cells is increasingly recognized, fully-established tumors can efficiently evade T cell response.
Significant efforts spanning several decades of research have been made to develop T cell-based therapies manufactured from donor-derived T cells.
The use of tumor-directed T cells engineered to express chimeric antigen receptors (CARs) represents, to date, one of the most successf…
KATHOLIEKE UNIVERSITEIT LEUVEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
INSTYTUT MEDYCYNY DOSWIADCZALNEJ I KLINICZNEJ IM MIROSLAWA MOSSAKOWSKIEGO POLSKIEJ AKADEMII NAUK
Poland, WARSZAWA
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
UNIVERSITAIR MEDISCH CENTRUM GRONINGEN
Netherlands, Groningen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
